May 15, Clinical Trials: Confidence vs. Cost (click to register)
At no time in our history have medicines played a greater role in the well-being of society at large. From a global perspective, life spans are greater than they have ever been yet some leveling of that trend appears to be occurring.
Nonetheless, even after extensive trials, there are findings of latent side effects or over-stated outcomes.
In the session, we will discuss the limitations of our knowledge and what emerging techniques will allow greater precision and assurance of success in the use of placebos, biostatistical analyses and objective biological metrics in evaluating potential new medicines for use in human populations.
An overview and discussion of the evolution and approaches towards best practices in designing trials using biomarkers and phenotypic screening in pharmaceutical settings for the development of newer
and more specific treatments will be the panel's focus.
Join the conversation on the approaches that are most effective. Are we capable of being predictive at any level concerning the full response humans have to new molecules from both Nature and man?
- Bruce Barton, Ph.D.,Professor in the Division of Biostatistics and Health Services Research and Director of the Quantitative Methods Core, University of Massachusetts Medical School
- Michael Sugarman, PhD, postdoctoral fellow at Edith Nourse Rogers Veterans Hospital, Bedford
- Mark Hediger, PhD, Principal, MEH Associates, Moderates
Bruce Barton, Ph.D., is currently a Professor in the Division of Biostatistics and Health Services Research as well as the Director of the Quantitative Methods Core in the Department of Quantitative Health Sciences at the University of Massachusetts Medical School. He is a biostatistician with over 40 years of experience in medical research, primarily in clinical trials. He has been the lead biostatistician on over 50 clinical trials, including studies in breast cancer, bladder cancer, cardiovascular disease and cardiovascular risk factors, stroke, traumatic brain injury, hepatitis C, alcoholic hepatitis, and many others. He has been involved in Phase I, II, and III clinical trials for both the NIH and pharmaceutical industry and has worked with industry to submit studies to the FDA. He has also been the Principal Investigator or Director of 34 Data Coordinating Centers, ranging from studies of 4 clinical sites to studies with over 150 clinical centers and in over 20 countries. He has published over 150 collaborative articles in medical journals and has served on over 250 NIH grant review committees.
Michael Sugarman, PhD is a clinical neuropsychologist who earned his doctoral degree from Wayne State University in Detroit, MI and is currently a postdoctoral fellow at Edith Nourse Rogers Veterans Hospital in Bedford, MA. His research interests includes placebo effects as they pertain to psychiatric conditions. In collaboration with the Program in Placebo Studies & Therapeutic Encounter at Harvard Medical School, he has conducted multiple meta-analyses examining placebo and antidepressant efficacy in depression, panic disorder, generalized anxiety disorder, obsessive-compulsive disorder, and others. His expertise also includes the examination of aspects of clinical trials and patient-provider interactions that have been identified as relevant to placebo effects.
June 19, 2017: Scientific & Medical Advances for An Aging Population
With 57 million — 18% ... 22% predicted by 2020…— of the population of the US over the 60 year old mark in 2010, where 60 is the new 40, what can we do/ is being done to slow down the aging process, even when living a healthy lifestyle?
The program looks at new medical devices, advances in pharmacology, and diagnotstic tools that we will all be glad exist! We are looking to cover:
1. Cosmetic surgery, botox and lasers
2. Alzheimers identification, treatment
3. Biologics that slow the aging process – brain, skin, bone…
Committee: Jerry Shapiro & Barbara Finer, co-chairs, Mark Hediger, Bruce Rogers, Rachit Ohri, David Howe, Jenn Fern